Stem Cell Therapy
A regenerative treatment using undifferentiated cells capable of self-renewal and differentiation into specialized tissue. In veterinary medicine, adipose-derived mesenchymal stem cells are most commonly used for osteoarthritis and tendon injuries in dogs.
Stem cell therapy in veterinary medicine involves harvesting, processing, and administering undifferentiated cells that have the capacity to self-renew and differentiate into multiple tissue types. The goal is tissue repair or regeneration in areas where the body’s natural healing mechanisms are insufficient.
Types of Stem Cells Used in Dogs
Adipose-Derived Mesenchymal Stem Cells (AD-MSCs)
The most commonly used type in veterinary practice. Harvested from the dog’s own fat tissue (autologous) via a minor surgical procedure, then processed to isolate the stromal vascular fraction (SVF) containing mesenchymal stem cells.
Bone Marrow-Derived MSCs
Harvested from the proximal humerus or iliac crest. Higher concentration of MSCs per volume than adipose tissue but requires a more invasive collection procedure.
Allogeneic (Donor) Cells
Some commercial products use stem cells derived from donor dogs, eliminating the need for surgical harvest from the patient. These products are typically culture-expanded and cryopreserved.
Mechanism of Action
Current understanding suggests that injected MSCs exert their therapeutic effects primarily through paracrine signaling rather than direct tissue differentiation:
- Anti-inflammatory cytokine secretion: MSCs release IL-10, TGF-beta, and other anti-inflammatory mediators that reduce local inflammation
- Immunomodulation: MSCs suppress activated immune cells, reducing autoimmune and inflammatory tissue destruction
- Growth factor release: secretion of factors that stimulate resident progenitor cells and angiogenesis
- Exosome release: MSCs secrete extracellular vesicles containing bioactive molecules that modulate tissue repair (exosome therapy is emerging as a related approach)
Clinical Evidence in Dogs
Osteoarthritis: the most studied application. Multiple studies demonstrate:
- Improved lameness scores in dogs with hip dysplasia and elbow dysplasia OA
- Reduced NSAID requirements in some patients
- Effects lasting 3-12 months in most reports (repeat treatments often needed)
- A 2016 randomized controlled trial (Vilar et al.) showed significant improvement in peak vertical force in dogs with hip OA treated with AD-MSCs vs. placebo
Tendon and ligament injuries: limited but promising data for cruciate ligament disease and tendinopathies
Limitations
- Cost: $2,000-5,000 per treatment, generally not covered by pet insurance
- Standardization: cell counts, viability, and processing methods vary between providers
- Regulatory status: FDA-CVM has not formally approved stem cell products for veterinary use; most are used under practice of medicine exemptions
- Durability: effects are often temporary, requiring repeat treatments
- Evidence quality: many studies are small, unblinded, and lack appropriate controls
The field shows genuine promise but has outpaced the rigor of its evidence base. Owners should seek practitioners who document outcomes and use verified cell processing protocols.